NPS Hopes For A Happy New Year With Catalysts And Growth Ahead
This article was originally published in The Pink Sheet Daily
Executive Summary
The new year is set to be a pivotal one for the rare disease specialist, which expects to launch its short bowel disease drug teduglutide in Europe and have a second product, Natpara, approved in the U.S.